Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Summary

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

Timeline

Start

2024-02-02

Primary completion

2024-06-25

Completion

2024-09-22

Outcome

Met primary endpoint

paper in the tocilizumab group (adjusted mean difference in cubic root volume [ml1/3] -0.41, 95% CI -0.79 to -0.03, P = 0.04 PMID 41687453 ↗

Publications

• Chu X, Lan J, Ma Z, Yin Y, Gu H, Baron JC, Liesz A, Wen C, Liu Y, Sun J, Wang N, Li C, Feng X, Li J, Wang B, Feng Y, Wu C, Dong X, Zhou C, Li C, Zhao W, Liu G, Fisher M, Liebeskind DS, Fang M, Jia X, Ma H, Ji X, Wu C; IRIS investigators. Effect of IL-6 receptor inhibition on infarct volume after endovascular treatment for ischaemic stroke: a phase 2, randomised, placebo-controlled trial. EBioMedicine. 2026 Mar;125:106167. doi: 10.1016/j.ebiom.2026.106167. Epub 2026 Feb 12.

Drugs

Indications